FFA
ACRS icon

Farther Finance Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Farther Finance Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.34K Sell
255
-920
-78% -$5.25K ﹤0.01% 5505
2026
Q2 		$6.22K Buy
1,175
+828
+239% +$3.69K ﹤0.01% 4678
2026
Q1 		$1.44K Sell
347
-51
-13% -$172 ﹤0.01% 5010
2025
Q4 		$1.2K Buy
398
+299
+302% +$755 ﹤0.01% 4866
2025
Q3 		$188 Hold
99
– – ﹤0.01% 4733
2025
Q2 		$141 Hold
99
– – ﹤0.01% 4264
2025
Q1 		$147 Hold
99
– – ﹤0.01% 4009
2024
Q4 		$246 Hold
99
– – ﹤0.01% 3608
2024
Q3 		$114 Hold
99
– – ﹤0.01% 3760
2024
Q2 		$114 Hold
99
– – ﹤0.01% 3583
2024
Q1 		$125 Buy
99
+34
+52% +$41 ﹤0.01% 3346
2023
Q4 		$68 Buy
+65
New +$198 ﹤0.01% 3349

Other funds holding ACRS

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Farther Finance Advisors's ACRS Position: Q3 2026 in Review

Farther Finance Advisors reduced its Aclaris Therapeutics (ACRS) stake by 78% in Q3 2026, selling an estimated $5.25K and leaving 255 shares worth $1.34K. The position accounts for ﹤0.01% of the portfolio, ranked #5505.

Farther Finance Advisors first reported a position in ACRS in Q4 2023 and has held it in 12 quarters since. The position peaked at $6.22K in Q2 2026. 3 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • Farther Finance Advisors held 255 shares of Aclaris Therapeutics worth $1.34K as of Q3 2026.
  • Farther Finance Advisors sold 920 Aclaris Therapeutics shares in Q3 2026, an estimated $5.25K.
  • Aclaris Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5505 holding.
  • Farther Finance Advisors first reported a position in Aclaris Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • Farther Finance Advisors's Aclaris Therapeutics position peaked at $6.22K in Q2 2026.
  • 3 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.